SlidesetViral Hepatitis and Liver DiseaseNew Combination Therapies in Hepatitis Delta Therapy - J. Glenn, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseNew Data From Combination Trials for Chronic Hepatitis B - P. Lampertico, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseasePatient Selection for Clinical Trials Based on Drug Class - F. Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhat Can We Learn by Deploying Immunological Analysis in Phase II Clinical Trials - A. Gehring, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseImmunotherapeutics in the Treatment of Chronic Hepatatis B - S. Browne, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseVBI-2601 Immunotherapeutic HBV Vaccine Candidate Overview - F. Diaz-Mitoma, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHBV Immunotherapeutic Vaccines (Lessons from HCV) - E. Barnes, PhD, FRCP, F. Med. SciView Slideset
SlidesetViral Hepatitis and Liver DiseaseA Novel Approach At Targeting the PD-1PD-l1 Pathway - PD-l1 Lna - AView Slideset
SlidesetViral Hepatitis and Liver DiseaseHBsAg Loss. A Predictor of Long-Term Clinical Outcomes - M. Peters, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHow to Handle Flares in HBV Trials With Novel Agents - Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseSafety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation - P. Mishra, MD, MPH, FAASLDView Slideset
SlidesetViral Hepatitis and Liver DiseaseBiological Insights Taught by Clinical Responses to Novel Hbv-Hdv Drugs - S. Urban, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseCore Inhibitors (Capsid Assembly Modulators) - Luisa Stamm, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseActive Site Polymerase Inhibitor Nucleotides (APSINs) - D. Mayers, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV - D. Manuilov, MDView Slideset
